Thr73

Site Information
AGQERFHtITTSYYR SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 471953

In vivo Characterization
Methods used to characterize site in vivo:	immunoassay ( 2 ) , mass spectrometry ( 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 ) , mutation of modification site ( 3 ) , phospho-antibody ( 2 , 3 , 4 , 5 , 6 , 7 , 8 ) , western blotting ( 2 , 3 , 4 , 5 , 6 , 7 , 8 )
Disease tissue studied:	neuroblastoma ( 3 ) , melanoma skin cancer ( 2 )
Relevant cell line - cell type - tissue:	'3T3-L1, differentiated' (adipocyte) ( 10 ) , 'fat, brown' ( 13 ) , 'neuron, cortical'-brain ( 6 ) , B16F10 ( 2 ) , brain ( 7 , 12 , 13 ) , BV2 (microglia) ( 4 ) , heart ( 13 ) , kidney ( 7 , 13 ) , lung ( 5 , 7 ) , MEF (fibroblast) ( 5 , 11 ) , Melan-a (melanocyte) ( 2 ) , Melan-Ink4a-1 ( 2 ) , melan-le (melanocyte) ( 2 ) , microglia ( 8 ) , muscle ( 18 , 19 ) , RAW 267.4 (macrophage) ( 20 ) , SH-SY5Y (neural crest) ( 3 ) , spleen ( 13 , 14 , 17 ) , thymus ( 15 , 16 )

Upstream Regulation
Regulatory protein:	RAB29 (human) ( 2 ) , RAB32 (human) ( 2 ) , RAB38 (human) ( 2 ) , SNCA (mouse) ( 8 )
Putative in vivo kinases:	LRRK2 (human) ( 2 , 3 , 4 , 5 , 6 , 7 )
Treatments:	GNE-7915 ( 5 ) , LRRK2-IN-1 ( 4 ) , MLI-2 ( 3 , 4 , 5 , 6 , 7 ) , Mn(2+) ( 4 ) , siRNA ( 2 )

Downstream Regulation
Effects of modification on biological processes:	apoptosis, induced ( 4 ) , autophagy, induced ( 4 ) , autophagy, inhibited ( 3 ) , signaling pathway regulation ( 4 )

References
1	Eguchi T, et al. (2024) The V-ATPase-ATG16L1 axis recruits LRRK2 to facilitate the lysosomal stress response. J Cell Biol 223 38227290 Curated Info
2	Unapanta A, et al. (2023) Endogenous Rab38 regulates LRRK2's membrane recruitment and substrate Rab phosphorylation in melanocytes. J Biol Chem 299, 105192 37625589 Curated Info
3	Kania E, et al. (2023) LRRK2 phosphorylation status and kinase activity regulate (macro)autophagy in a Rab8a/Rab10-dependent manner. Cell Death Dis 14, 436 37454104 Curated Info
4	Pajarillo E, et al. (2023) The role of microglial LRRK2 kinase in manganese-induced inflammatory neurotoxicity via NLRP3 inflammasome and RAB10-mediated autophagy dysfunction. J Biol Chem 299, 104879 37269951 Curated Info
5	Ho PW, et al. (2022) Long-term inhibition of mutant LRRK2 hyper-kinase activity reduced mouse brain α-synuclein oligomers without adverse effects. NPJ Parkinsons Dis 8, 115 36088364 Curated Info
6	Boecker CA, et al. (2021) Increased LRRK2 kinase activity alters neuronal autophagy by disrupting the axonal transport of autophagosomes. Curr Biol 31, 2140-2154.e6 33765413 Curated Info
7	Kluss JH, et al. (2021) Preclinical modeling of chronic inhibition of the Parkinson's disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo. Mol Neurodegener 16, 17 33741046 Curated Info
8	Kim C, et al. (2020) LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies. Sci Transl Med 12 33055242 Curated Info
9	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
10	Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20 23684622 Curated Info
11	Wu X, et al. (2012) Investigation of receptor interacting protein (RIP3)-dependent protein phosphorylation by quantitative phosphoproteomics. Mol Cell Proteomics 11, 1640-51 22942356 Curated Info
12	Goswami T, et al. (2012) Comparative phosphoproteomic analysis of neonatal and adult murine brain. Proteomics 12, 2185-9 22807455 Curated Info
13	Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89 21183079 Curated Info
14	Guo A (2009) CST Curation Set: 8166; Year: 2009; Biosample/Treatment: tissue, spleen/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
15	Guo A (2009) CST Curation Set: 8170; Year: 2009; Biosample/Treatment: tissue, thymus/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
16	Guo A (2009) CST Curation Set: 8169; Year: 2009; Biosample/Treatment: tissue, thymus/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
17	Guo A (2009) CST Curation Set: 8165; Year: 2009; Biosample/Treatment: tissue, spleen/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
18	Guo A (2009) CST Curation Set: 8162; Year: 2009; Biosample/Treatment: tissue, muscle/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
19	Guo A (2009) CST Curation Set: 8163; Year: 2009; Biosample/Treatment: tissue, muscle/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
20	Trost M, et al. (2009) The phagosomal proteome in interferon-gamma-activated macrophages. Immunity 30, 143-54 19144319 Curated Info